Rafal R Sicinski

6362350, Mar 26, 2002

Nov 10, 1999

09/437307

Hector F. DeLuca - Deerfield WI
Rafal R. Sicinski - Madison WI
Hazel Holden - Fitchburg WI
James Brian Thoden - Madison WI

Wisconsin Alumni Research Foundation - Madison WI

C07C40100

552653, 514167

A method of purifying 1,24(S)-dihydroxyvitamin D to obtain 1,24(S)-dihydroxyvitamin D in crystalline form. The method includes the steps of boiling a solvent under inert atmosphere, dissolving a product containing 1,24(S)-dihydroxyvitamin D to be purified in the solvent, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of 1,24(S)-dihydroxyvitamin D crystals, and recovering the 1,24(S)-dihydroxyvitamin D crystals. The purification technique involves using one of several binary solvent systems, namely, acetone and hexane, 2-propanol and hexane, or ethyl formate and petroleum ether.

6432936, Aug 13, 2002

Jan 20, 1999

09/233738

Hector F. DeLuca - Deerfield WI
Rafal R. Sicinski - Madison WI
Hazel Holden - Fitchburg WI
James Brian Thoden - Madison WI

Wisconsin Alumni Research Foundation - Madison WI

A61K 31592

514167, 552653

A method of purifying 1-hydroxyvitamin D to obtain 1-hydroxyvitamin D in crystalline form. The method includes the steps of boiling a solvent selected from the group consisting of ethyl formate, ethyl acetate and a 2-propanol-hexane mixture under inert atmosphere, dissolving a product containing 1-hydroxyvitamin D to be purified in the. solvent, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of 1-hydroxyvitamin D crystals, and recovering the 1-hydroxyvitamin D crystals. Optionally, petroleum ether may be added to the solvent after dissolving the product to be purified in the solvent.

7232810, Jun 19, 2007

Aug 18, 2004

10/922114

Hector F. DeLuca - Deerfield WI, US
Rafal R. Sicinski - Madison WI, US
Sumithra Gowlugari - Fremont CA, US

Wisconsin Alumni Research Foundation - Madison WI

A61K 31/59
C07C 401/00

514167, 552653

2-Methylene-19-nor-24(S) and 24(R) derivatives of 1α,25-dihydroxyvitamin Dare disclosed. These compounds are characterized by minimal bone calcium mobilization activity and relatively high intestinal calcium transport activity. This results in novel therapeutic agents for the treatment of diseases such as renal osteodystrophy, autoimmune diseases, and osteoporosis. These compounds also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as anticancer agents and for use treating skin diseases such as psoriasis.

7713951, May 11, 2010

Apr 9, 2004

10/821828

Hector F. DeLuca - Deerfield WI, US
Rafal Barycki - Madison WI, US
Pawel K. Grzywacz - Madison WI, US
Lori A. Plum - Madison WI, US
Rafal R. Sicinski - Madison WI, US

Wisconsin Alumni Research Foundation - Madison WI

A61K 31/59
C07C 401/00

514167, 552653, 514825

2-alkylidene-18,19-dinor-vitamin D compounds are disclosed as well as pharmaceutical uses for these compounds and methods of synthesizing these compounds. These compounds are characterized by low bone calcium mobilization activity and high intestinal calcium transport activity. This results in novel therapeutic agents for the treatment and prophylaxis of diseases where bone formation is desired, particularly osteoporosis, as well as autoimmune diseases such as multiple sclerosis, diabetes mellitus and lupus. These compounds also exhibit pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis. These compounds also increase both breaking strength and crushing strength of bones evidencing use in conjunction with bone replacement surgery such as hip and knee replacements.

20010051738, Dec 13, 2001

Jun 22, 2001

09/887297

Hector DeLuca - Deerfield WI, US
Rafal Sicinski - Madison WI, US
Hazel Holden - Fitchburg WI, US
James Thoden - Madison WI, US

Wisconsin Alumni Research Foundation - Madison WI

C07C401/00

552/653000

A method of purifying 1,24(S)-dihydroxyvitamin Dto obtain 1,24(S)-dihydroxyvitamin Din crystalline form. The method includes the steps of boiling a solvent under inert atmosphere, dissolving a product containing 1,24(S)-dihydroxyvitamin Dto be purified in the solvent, cooling the solvent and dissolved product below ambient temperature for a sufficient amount of time to form a precipitate of 1,24(S)-dihydroxyvitamin Dcrystals, and recovering the 1,24(S)-dihydroxyvitamin Dcrystals. The purification technique involves using one of several binary solvent systems, namely, acetone and hexane, 2-propanol and hexane, or ethyl formate and petroleum ether.

47192054, Jan 12, 1988

Nov 4, 1985

6/794325

Hector F. DeLuca - Madison WI
Heinrich K. Schnoes - Madison WI
Rafal R. Sicinski - Madison WI
Yoko Tanaka - Madison WI

Wisconsin Alumini Research Foundation - Madison WI

A61K 3159
C07J 900

514167

Novel 1-hydroxylated vitamin D compounds containing a 22, 23-cis double bond in the side chain are provided. The compounds are characterized by an unexpectedly high binding affinity for the protein receptor forecasting their ready applicability as substitutes for vitamin D or various of its metabolites in their various known applications and in the treatment of various metabolic bone diseases.

46891803, Aug 25, 1987

Nov 4, 1985

6/794324

Hector F. DeLuca - Madison WI
Heinrich K. Schnoes - Madison WI
Rafal R. Sicinski - Madison WI
Yoko Tanaka - Madison WI

Wisconsin Alumni Research Foundation - Madison WI

C07J 900

2603972

The invention provides a novel vitamin D derivative, 1. alpha. ,25-dihydroxy-22Z-dehydrovitamin D. sub. 2. The compound is characterized by unexpectedly high ability to raise serum calcium levels. The compound could therefore, find ready application as a substitute for vitamin D or its metabolites in the treatment of metabolic bone diseases or in other of their known applications.

47691816, Sep 6, 1988

Nov 7, 1983

6/549047

Hector F. DeLuca - Madison WI
Heinrich K. Schnoes - Madison WI
Rafal R. Sicinski - Madison WI
Yoko Tanaka - Madison WI

Wisconsin Alumni Research Foundation - Madison WI

C07J 900

2603972

The invention is directed to the preparation of hydroxylated compounds of the vitamin D. sub. 2 series and specifically to a process for synthesizing 1. alpha. ,25-dihydroxyvitamin D. sub. 2, 1. beta. ,25-dihydroxyvitamin D. sub. 2, their corresponding 5,6-trans isomers and the C-24 epimers of these compounds. The hydroxylated vitamin D. sub. 2 compounds obtained exhibit vitamin D-like activity and can be substituted for vitamin D. sub. 3 or various of its known metabolites where such compounds are applied.